Glazer Capital, LLC Reports 4.85% Stake in KalVista Pharmaceuticals, Inc. (KALV)

On June 10, 2026, Glazer Capital, LLC and its Managing Member, Paul J. Glazer, filed a Schedule 13G regarding their holdings in KalVista Pharmaceuticals, Inc. (KALV). The filing indicates that as of the event date on June 3, 2026, the reporting persons beneficially owned 2,581,700 shares of common stock, representing a 4.85% ownership stake in the company. The filing specifies that Glazer Capital serves as the investment manager for various funds and managed accounts that hold these shares. Notably, the reporting persons indicated that they may have previously been deemed to beneficially own more than 5% of the outstanding shares on the date of the event necessitating this filing; however, as of the filing date, their ownership has fallen below the 5% threshold. The shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. All reported shares are held with shared voting and dispositive power.